Each sublingual tablet contains buprenorphine hydrochloride equivalent to 0.2 mg of buprenorphine.
Each ml of ampoule contains buprenorphine hydrochloride 324 μg, equivalent to 300 μg of buprenorphine base.
Tablet: Buprenorphine hydrochloride, the active ingredient in Temgesic Sublingual Tablets is a potent, long-acting analgesic, which exhibits powerful narcotic agonistic and antagonistic characteristics. Buprenorphine is more potent than morphine, and at therapeutically equivalent doses has similar onset of action and quality of analgesia, but a longer duration of action; when given by the parenteral route, 0.3 mg of buprenorphine is approximately equivalent to 10 mg of morphine sulfate in analgesic and respiratory depressant effects in adults.
Temgesic Sublingual Tablets allow buprenorphine to be absorbed through the buccal mucosa within minutes.
Ampoule: Buprenorphine hydrochloride is a white to off-white powder, weakly acidic in character and with a limited solubility in water.
Temgesic Injection is a terminally sterilised solution for injection.
Excipients/Inactive Ingredients: Tablet: Lactose, mannitol, maize starch, povidone, citric acid, magnesium stearate, sodium citrate, purified water, alcohol (96%).
Ampoule: Dextrose, hydrochloric acid, water for injection.